Saturday, December 6, 2008

videos for Accuray technology

Delivering fully-automated non-coplanar treatments in routine clinical practice, the CyberKnife System treats even the most complex tumors with unrivaled conformality, dose gradient, and healthy tissue preservation.

icon [7.51]
Lung Radiosurgery
icon [7.54]
Prostate Radiosurgery

uWink Announces Odd-Lot Tender Offer


uWink, Inc. (OTCBB: UWKI) announced today that it will commence anodd lo tender offer to purchase all shares of its common stock held by persons owning 99 shares or fewer on the close of business as of December 1, 2008. The Company will pay $0.50 for each share properly tendered, plus an additional $20 to each stockholder who properly tenders uWink shares as a reimbursement of its estimated annual servicing costs (transfer agent, proxy statements, etc.) for each stockholder of record.

The purpose of the odd-lot tender offer is to reduce the number of uWink stockholders of record and reduce or eliminate future servicing fees and SEC reporting costs stated Nolan Bushnell, Chairman and Chief Executive Officer.We estimate that odd-lot stockholders who own less than 100 shares represent over 66% of our record stockholder base but only approximately 0.04% of our total shares outstanding

If we are successful in reducing our total stockholders of record under 500, uWink plans to deregister its common stock with the Securities and Exchange Commission. As a result of these actions, we expect to save considerable costs related to SEC reporting requirements, costs associated with implementing and complying with the Sarbanes Oxley Act and stock registrar costs. We also expect to reduce the significant amount of management time devoted to these activities stated Mr. Bushnell.

In addition, if we are successful in deregistering, we intend to spin-off our Technology Licensing business, via a stock dividend, to our shareholders as a separate non-reporting company. We are still in the early stages of the development of each of our operating businesses and we believe that spinning off our Technology Licensing business, and eliminating the costs associated with being a reporting company for each of our operating businesses, will improve the prospects for raising growth capital, as well as allow each of our operating businesses to compete more effectively in its respective markets stated Mr. Bushnell.

Following deregistration, uWink common stock will no longer be eligible for quotation on the OTCBB; but may be quoted in the Pink Sheets Electronic Quotation System. However, the Company cannot predict whether or when this will occur or that an active trading market will exist for its common stock after deregistration. Moreover, the Company intends to effect the spin-off of its Technology Licensing business such that shareholders will receive restricted shares of the spin-off company so that no trading market will develop for the common stock of the spin-off company. The Company expects to provide (and intends that the spin-off company will provide) its stockholders with annual unaudited financial information following its deregistration from the SEC.

The tender offer is not conditioned on the receipt of any minimum number of shares tendered. The Company has reserved the right to withdraw the offer if it determines that it is inadvisable to proceed with the offer for any reason.

If after completion of the purchase offer there are fewer than 500 stockholders of record, uWink intends to deregister its common stock with the Securities and Exchange Commission and the spin-off to shareholders of its Technology Licensing business as a separate non-reporting company. If, after the completion of the tender offer, uWink has more than 500 stockholders, the Board of Directors may consider other options to reduce the number of stockholders.

Stockholders and investors are urged to read uWink's Schedule 13E-3 being filed today with the SEC in connection with this tender offer, which includes the Offer to Purchase for Cash. These materials contain important information including the various terms and conditions to the offer.

Investors may obtain copies of uWink's Schedule 13E-3 for free from the SEC at the SEC's website or from the Company. Questions or requests for documents also may be directed to Nancy Nino of the Company at (818) 909-6030 x 102, or in writing to uWink, Inc., 16106 Hart Street, Van Nuys, CA 91406.

This press release is for informational purposes only and is not an offer to buy or a solicitation of an offer to sell any shares of uWink's common stock. The offer is being made solely by the Offer to Purchase for Cash and the accompanying Authorization Card, each dated December 5, 2008, which are being mailed to stockholders. The tender offer will expire at 5:00 p.m., Eastern Time, on Thursday, January 15, 2009, unless otherwise extended or earlier terminated. Eligible stockholders who would like to accept the offer must tender all shares that they own. Partial tenders will not be accepted.


Common Stock 11/25/2008
40,100 A$ 39.409


A = acquired

Friday, December 5, 2008

What benefits have you experienced from the pyratine 6?

from the Rosacea Forum:

>>Today only, December 4th, 1- 877- skinfo4, has Pyratin-6 lotion and cream and other skin items on sale for 15% off. I just ordered myself the lotion. I've used Dr. Amy Taub's site the past year to obtain this.

I've been using the lotion since about last March. It is the only moisterizer I have ever been able to use for any length of time without breaking out or irritation. I tried the cream a couple of times and it was a little too rich for my skin. Maybe I will try it again after Christmas since we are getting chilly here and my face is a little dryer. I use a pea size of the lotion on my damp face. I really am pleased. The lady that took the order asked where I had heard about it, which was on this web site. This is my 3rd order with them. I still have some in my second tube, but couldn't resist the sale!!

Thursday, December 4, 2008


With six different premium bandwidth providers delivered through two diverse points to our private datacenter, Gigenet's 100% uptime network provides the performance and reliability that you expect for your hosting infrastructure.

    Network POPS

  • 111 N. Canal St, 2nd Floor, Connectivity Multiple OC192 (10 Gigabit Ethernet) expandable to 480Gb/s
  • 350 Cermack, 5th Floor, Equinix, Connectivity Multiple OC192 (10 Gigabit Ethernet) expandable to 480Gb/s
  • Connectivity Between 350 Cermack and 111 N. Canal , Dark Fiber 10 Gigabit Ethernet, expandable to 80Gb/s
  • Future Expansion to Elk Grove equinix facility on Lunt avenue

Tokyo Financial Exchange: Announcement Of Participants In Remote Membership Program


In order to facilitate market access and increase liquidity in its flagship products 3 month Euroyen futures and options, Tokyo Financial Exchange (TFX) has initiated a remote membership program and collocation services. TFX is pleased to announce the first trading firms to apply for remote membership.


  • G.H. Financials Limited (Based in London)
  • Advantage Futures LLC (Based in Chicago)

    These companies are currently applying to register as a financial instruments business with the Financial Services Agency in Japan. After applying to TFX and connecting to the TFX host, they will be ready to trade. TFX is targeting the end of the first quarter of 2009 as the time to go live.

    TFX has obtained permission to market remote membership from the FSA in the United Kingdom and the CFTC in the U.S.A. By the start of next year, TFX hopes to place an application to gain permission from MAS in Singapore and thus expand remote membership into the Asia region.

    Remote Membership Program

    This is a program where overseas investors, who have no offices in Japan, will be able to become members of the exchange and access the TFX market directly to trade 3 month Euroyen futures and options. The fee for registration as a member of TFX has been reduced to zero. Remote members must clear through an existing TFX clearing member in Japan and must register as a Category Two Financial Instruments Business with a legal representative based in Japan.

    Colocation Services

    As a colocation site, TFX is endorsing KVH and Equinix datacenters. Both companies have global coverage and comprehensive service listings.

    TFX Connectivity

    GL Trade is offering a complete global network connectivity solution to TFX. Patsystems is also offering a solution to connect to TFX, excluding a global network. Trading Technologies is targeting connectivity support to TFX by the end of the first quarter of 2009. In addition, RTS and FFastfill are currently starting connectivity procedures. For those traders seeking network solutions, KVH, BT and TNS are all offering their services.

    G.H. Financials

    G.H. Financials Ltd. was established in 1993 as a clearing member of LIFFE. The company has gained considerable experience in electronic trading. The company’s principal activity is the provision of trading access on electronic derivatives exchanges to professional traders, the clearing and settlement of their trades, and providing the services necessary to support such market activity. The company has exchange memberships with NYSE-Euronext Liffe, NYSE-Euronext Paris, Eurex, ICE and Montreal Exchange.

    Advantage Futures

    Advantage Futures is the Chicago-based premier futures brokerage firm designed exclusively by trading industry professionals for institutions, hedge funds, CTAs, proprietary trading groups and professional traders. The firm was founded in 2003 and in the first 4½ years of operation, cleared over one billion contracts. Advantage Futures strives to grow through its dedication to excellence in client service. Advantage Futures has exchange memberships with CME, NYSE-Euronext Liffe, Eurex, ICE and Montreal Exchange.
  • Tuesday, December 2, 2008

    SoftLayer discloses 2008 financial summary; set for larger push in 2009

    from Tier 1 Research:

    >>We recently spoke with SoftLayer and the company indicated that it was set to hit in the range of $54-56m in annual revenues for 2008 and is moving into 2009 on a (annual) run rate of over $60m. SoftLayer's growth has been impressive, with the preceding year's revenues coming in .....

    Monday, December 1, 2008

    uWink's Chances of Survival

    a new analisys of uWink by Chris Fernandez on Seeking Alpha:

    >>It’s been a recurring theme with the large scale selling in the market but uWink (NASDAQ: UWKI.OB) in particular, as those that own these stocks panic and try to make sense of their investments.

    We’re at that juncture where it’s time to once again check in on uWink and their latest quarterly earnings release (or rather the 10-Q), and what this means for our investment going forward.

    Sunday, November 30, 2008

    Is CyberKnife Ready for Prime Time in Prostate Cancer?

    from the Wall Street Journal:

    >>Is CyberKnife Ready for Prime Time in Prostate Cancer?

    This morning’s Washington Post tells the tale of prostate cancer and CyberKnife, a $4 million machine designed to deliver high-dose, targeted radiation to kill tumors. Some hospitals that initially used the machine for brain and spinal tumors difficult to treat any other way are now using it to treat prostate cancer, which can be well treated by more conventional methods.

    “This is really pushing the envelope,” Anthony Zietman, president-elect of the American Society for Therapeutic Radiology and Oncology (ASTRO) told the Post. “It might be as good and more convenient. It may be better and more convenient. But it could turn out to be a disaster. No one knows.”


    comments section:

    Prostate Cancer is a hihgly curale treatment if ofund early Seed implantation, surgery and external beam radiaton are tries and true treatments with thousands of patients treated and long term results known. The cyberknife has no proven track record and patients should be extremely cautious about the enthusiatic claims made by the owners of these machines. For example we are just learning now about the detrimental effects long term on patients who have external beam radiation The Cyberknife may be worse

    Comment by Peter Grimm - November 28, 2008 at 10:10 am

    I am a PhD physicist who worked with radiation effects for more than two decades. When diagnosed with early stage prostate cancer over a year ago, I rejected most radiation treatments based on that experience. After investigating the CyberKnife, it was a “no brainer” for me. The objections that I uncovered all appeared motivated by either uninformed fear or economic motivation. Follow-up after CyberKnife treatment has confirmed the efficacy of my decision. Comment by doug10 - November 29, 2008 at 2:19 pm

    Experts Debate CyberKnife for Prostate Cancer

    From the Washington Post:

    >>But Georgetown, along with Virginia Hospital Center and others around the country, is now aggressively marketing the $4 million machine, known as the CyberKnife, for early prostate cancer, one of the most common cancers. That trend has sparked an intense debate about whether it represents an important advancement or the latest example of an expensive and potentially profitable new technology proliferating too soon.

    While its advocates say the CyberKnife offers prostate cancer patients a safe and effective -- and much more convenient -- alternative to traditional radiation treatment, many experts fear that it could leave many men unnecessarily vulnerable to recurrences or potentially serious complications.

    Nokia 5800 XpressMusic First Impressions


    >>In short, it has a great sensitivity level that is very adequate to regular taps, and I found myself not looking for the stylus to use it, even for typing: the 5800 was in my hands for a mere 30 minutes, and I was hammering the on-screen keyboards in no time. Tactile feedback was really nice, and not annoying like I imagined it would be. It’s a small vibration that you can only perceive if you focus on it, but when you forget about it, you find yourself unconsciously getting aware of the taps and the screen’s response, which is pretty cool.